Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
740 participants
INTERVENTIONAL
2025-10-20
2032-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Sirolimus-Eluting Stent vs. Intravascular Brachytherapy in In-Stent Restenotic Coronary Artery Lesions(SISR)
NCT00231257
Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III (LONG-DES-III)
NCT01078038
Sirolimus-coated Balloon Versus Drug-eluting Stent in Native Coronary Vessels
NCT04893291
Treatment of Coronary In-stent Restenosis (ISR) by a Sirolimus Coated or a Paclitaxel Coated Balloon
NCT03242096
Sirolimus-Coated Balloon Versus Paclitaxel-Coated Balloon for the Treatment of Coronary In-Stent Restenosis
NCT04240444
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Virtue SAB
Coronary PCI, Sirolimus AngioInfusion Balloon (SAB)
Virtue Sirolimus AngioInfusion Balloon
Percutaneous Coronary Intervention
AGENT™ DCB
Coronary Angioplasty, AGENT™ Paclitaxel Drug-Coated Balloon (DCB)
AGENT™ Paclitaxel Drug-Coated Balloon
Percutaneous Coronary Intervention
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Virtue Sirolimus AngioInfusion Balloon
Percutaneous Coronary Intervention
AGENT™ Paclitaxel Drug-Coated Balloon
Percutaneous Coronary Intervention
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The target lesion is in a vessel with a reference vessel diameter ≥ 2.0 mm and ≤ 4.0 mm by visual assessment.
* The subject has only one critical ISR lesion.
* The subject may have one other critical lesion in a non-target vessel that must be treated before the Target Lesion (TL).
* Target lesion length must be ≤ 26 mm and must be completely coverable by only one Virtue® or AGENT™ balloon. The balloon can extend up to 5 mm proximal or distal beyond the edge of the target stented length.
* The target lesion must have one of the following:
* Visually estimated stenosis of ≥ 70% and \<100% diameter stenosis, OR
* Visually estimated stenosis ≥ 50% and \< 70% with one of the following:
* abnormal fractional flow reserve (FFR) including Angio based FFR ≤ 0.80, or;
* abnormal instantaneous wave-free ratio (iFR) or resting full-cycle ratio (RFR) ≤ 0.89, or;
* abnormal stress or imaging stress test, or;
* ischemic symptoms referable to the target lesion
* Involved in a NSTEMI or Acute Coronary Syndrome (ACS) event with decreasing enzymes
* Target lesion must be successfully pre-treated according to standard of care with an achieved residual stenosis of ≤ 30% by visual estimate with TIMI grade flow of 3 prior to randomization.
Exclusion Criteria
* Subject was treated by PCI or another coronary intervention within the last 30 days.
* Planned PCI or CABG after the index procedure.
* Subjects with STEMI \< 72 hours prior to index procedure and those with NSTEMI who have increasing biomarkers within 12 hours of the index procedure.
* If single-layer ISR, any previous treatment (other than balloon angioplasty alone) of the target vessel for restenosis. If double-layer ISR, any treatment (other than balloon angioplasty alone) of the double-layer ISR restenosis.
* Target lesion is located within a saphenous vein graft or an arterial graft.
* Thrombus is present in the target vessel.
* \> 50% stenosis of an additional lesion proximal or clinically significant distal (\>2.0mm RVD) to the target lesion.
* A dissection in the target lesion requiring treatment with a stent post pre-dilatation.
* The target ISR lesion has more than two layers of previously placed stents.
* Subject has critical unprotected left main coronary artery disease.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Orchestra BioMed, Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dean Kereiakes, MD
Role: PRINCIPAL_INVESTIGATOR
Lindner Center for Research at Christ Hospital
Allen Jeremias, MD
Role: PRINCIPAL_INVESTIGATOR
St. Francis Hospital & Heart Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St. Francis Hospital
Roslyn, New York, United States
The Lindner Center for Research at Christ Hospital
Cincinnati, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
E Haag
Role: primary
T Buchtmann
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Protocol - 0072
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.